

BIOPHARMICA LIMITED

Bridging Biotechnology Borders

ASX Announcement
November 26 2004

Scientists Win Grant Recognition

ACN 085 912 002

A number of scientists working with ASX listed biomedical commercialisation business BioPharmica Limited (BPH) across a range of biomedical projects have recently received grant recognition of the importance of their research and commercialisation work.

The company is working with world leading researchers at universities, hospitals and medical institutes in cancer, infectious disease, anaesthesia monitoring and other biomedical research.

BioPharmica is partnered with Cortical Dynamics and Dr David Liley to develop a monitor to assist anaesthetists to maintain patients at the correct level of unconsciousness during surgery to ensure patients do not wake unexpectedly.

The Australian and New Zealand College of Anaesthetists (Anzca) has awarded scientist and inventor Dr Liley (in conjunction with A/Prof Kate Leslie) a grant to assist in quantifying the effect of nitrous oxide on the depth of anaesthesia. Trials are expected to commence at the Royal Melbourne Hospital.

In addition the Australian Research Council has also provided Dr Liley with a grant of \$247,000 towards further development of his research into brain electrical activity. Telstra has also recently awarded Cortical Dynamics a prize in the Royal Melbourne Institute of Technology business planning competition.

The Federal Government Biotechnology Innovation Fund (BIF) has recently awarded BioPharmica's project with Diagnostic Array Systems a \$206,000 grant to determine the analytical capability of its bacterial DNA test for infectious diseases. In using bacterial DNA the diagnostic testing process can potentially be more accurate and timely to enable doctors to improve patient treatment of bacterial diseases such as pneumonia.

Additionally the Diabetes Australia Research Trust has recently awarded project collaborators Dr Paul Stoddart and Swinburne University of Technology with a grant to assist in the application of a SERS Optical Fibre towards a minimally invasive glucose biosensor.

BioPharmica is also working with the University of Western Australia and the Western Australian Institute for Medical Research (WAIMR). WAIMR is a venture including the Royal Perth Hospital, Sir Charles Gairdner Hospital, Fremantle Hospital and the University of Western Australia.

In recognition of its potential in detecting and treating cancer the research has previously received over \$1,000,000 in funding from the NHMRC, Cancer Council of WA, the National Breast Cancer Foundation and the Medical Research Foundation of Royal Perth Hospital. The research is based on the candidate tumour suppressor gene HLS5.

Managing Director David Breeze said, "recent recognition of the scientists we are working with from a number of independent bodies is a strong indication of the promise and importance of their research. We are very pleased with the progress of our cancer and other projects since listing in August and have laid the foundation for a very active period ahead".

The company is continuing to focus on structural work ahead of further applications for biotechnology grants of a significant financial nature as it commercialises the various biomedical research held within its portfolio.

David Breeze

Managing Director
BioPharmica Limited

Level 2, 30 Hasler Road,
Osborne Park, Western Australia 6017

PO Box 1534,
Osborne Park, Western Australia 6916

Telephone +61 (08) 9244 9631

Facsimile +61 (08) 9244 9782

Email admin@biopharmica.com.au

Internet www.biopharmica.com.au